Nocion completes patient enrolment in Phase IIb ASPIRE trial

Phase 2taplucainiumPositive

AI Analysis

Summary

Nocion Therapeutics has completed patient enrolment in its Phase IIb ASPIRE trial evaluating taplucainium for renal and urothelial cell carcinoma. This milestone represents progress toward data readout from the study.

Clinical Trial Data

Phase

Phase IIb

Outcome Details

Patient enrolment completed in Phase IIb ASPIRE trial

Importance:5/10

Sentiment:

0.30

Clinical DevelopmentOncologyPatient EnrollmentPhase IIb

Related Companies

$ASBP $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on May 6, 2026 8:48 AM

Read Original